Trial Profile
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary) ; Timolol
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIS; ARTEMIS 1
- Sponsors Allergan
- 01 Jan 2023 Results from NCT02247804 and NCT02250651; evaluating the time course of biodegradation of an intracameral, biodegradable, sustained-release bimatoprost implant that lowers intraocular pressure without the need for daily eye drops, published in the Journal of Ocular Pharmacology and Therapeutics
- 28 May 2022 Results of a pooled analysis of data from 2 phase III studies and one phase I/II study (NCT02247804, NCT02250651, and NCT01157364) assessed the single administration of intracameral Bimatoprost implant 10 µg in patients with Open-Angle Glaucoma or Ocular Hypertension, published in the Ophthalmology and Therapy
- 27 Apr 2021 According to an AbbVie media release, data from the new analyses of the Phase 3 ARTEMIS studies examining the duration of intraocular pressure (IOP) lowering and biodegradation kinetics of DURYSTA, will be presented at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting.